SciSparc Shareholders Approve Merger with AutoMax
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
SciSparc Ltd. ( (SPRC) ) just unveiled an announcement.
On August 28, 2025, SciSparc Ltd. announced that its shareholders approved a merger with AutoMax Motors Ltd., a leading parallel vehicle importer in Israel. This strategic merger, initially agreed upon in April 2024, will result in SciSparc acquiring 100% of AutoMax’s share capital, marking a significant expansion into the automotive sector. The merger aligns with SciSparc’s strategy to diversify its portfolio and capitalize on the growing electric vehicle market in Israel. The transaction is expected to enhance shareholder value, with SciSparc shareholders holding a majority stake in the combined entity. The merger’s completion is contingent upon customary closing conditions, including court and shareholder approvals.
More about SciSparc Ltd.
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders, utilizing cannabinoid pharmaceuticals. The company is involved in drug development programs for conditions such as Tourette Syndrome, Alzheimer’s disease, and autism spectrum disorders. Additionally, SciSparc holds a controlling interest in a subsidiary that sells hemp seed oil-based products on Amazon.
Average Trading Volume: 54,946
Technical Sentiment Signal: Sell
Current Market Cap: $2.26M
For detailed information about SPRC stock, go to TipRanks’ Stock Analysis page.
